Provectus Pharmaceuticals is a biopharmaceutical company specializing in the development of oncology and dermatology therapies. PV-10, the company’s novel oncology drug, is designed to selectively target and destroy cancer cells without harming the surrounding healthy tissue. Provectus has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications and recently completed Phase 2 trials of PV-10 as a metastatic melanoma therapy and PH-10 as a topical atopic dermatitis and psoriasis treatment. For more information, visit the company’s Web site at www.pvct.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: